"The voice of oncology in Massachusetts."

FDA has approved FRUZAQLA™ (fruquintinib), an oral therapy for adult patients with previously treated metastatic colorectal cancer (mCRC)

November 13, 2023 12:39 PM | Katy Monaco (Administrator)

The Food and Drug Administration approved fruquintinib (FRUZAQLA™, Takeda Pharmaceuticals, Inc.) for adult patients with metastatic colorectal cancer (mCRC) who received prior fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy. Read More.

Please see full Prescribing Information.  To learn more about FRUZAQLA, please visit fruzaqlahcp.com.

Massachusetts Society of Clinical Oncologists ©2023

860 Winter Street, Waltham, MA, 02451
Tel: 781.434.7329  |  email: msco@mms.org

Powered by Wild Apricot Membership Software